Illumina (NASDAQ:ILMN) had its price objective decreased by research analysts at Barclays from $390.00 to $350.00 in a note issued to investors on Thursday, BenzingaRatingsTable reports. The firm presently has an “overweight” rating on the life sciences company’s stock. Barclays‘s target price points to a potential upside of 32.26% from the stock’s current price.
A number of other equities research analysts have also recently issued reports on the company. Piper Sandler upped their price objective on Illumina from $341.00 to $370.00 and gave the stock an “overweight” rating in a research note on Thursday, January 9th. Credit Suisse Group reiterated a “buy” rating and set a $340.00 price objective on shares of Illumina in a research note on Tuesday, February 4th. Citigroup dropped their price objective on Illumina from $350.00 to $250.00 and set a “buy” rating on the stock in a research note on Friday, March 20th. BidaskClub cut Illumina from a “strong-buy” rating to a “buy” rating in a research note on Friday, January 31st. Finally, Cowen reiterated an “outperform” rating and set a $335.00 price objective (up previously from $320.00) on shares of Illumina in a research note on Wednesday, December 18th. Three equities research analysts have rated the stock with a sell rating, three have given a hold rating and thirteen have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $329.81.
NASDAQ ILMN traded up $16.31 during trading on Thursday, hitting $264.63. The stock had a trading volume of 86,618 shares, compared to its average volume of 1,837,115. The company has a market capitalization of $37.36 billion, a PE ratio of 39.12, a P/E/G ratio of 1.86 and a beta of 1.15. The company’s 50-day moving average price is $270.89 and its two-hundred day moving average price is $301.01. The company has a debt-to-equity ratio of 0.40, a quick ratio of 6.15 and a current ratio of 6.69. Illumina has a 12 month low of $196.78 and a 12 month high of $380.76.
Illumina (NASDAQ:ILMN) last released its earnings results on Wednesday, January 29th. The life sciences company reported $1.70 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.58 by $0.12. The firm had revenue of $953.00 million for the quarter, compared to analysts’ expectations of $950.16 million. Illumina had a return on equity of 22.34% and a net margin of 28.27%. The business’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.32 EPS. As a group, equities analysts anticipate that Illumina will post 6.85 earnings per share for the current fiscal year.
In related news, SVP Susan H. Tousi sold 200 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $325.00, for a total value of $65,000.00. Following the sale, the senior vice president now owns 38,465 shares in the company, valued at approximately $12,501,125. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Oene Mark Van sold 625 shares of the stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $300.24, for a total value of $187,650.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,867 shares of company stock worth $573,756. 0.38% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of ILMN. Voya Investment Management LLC raised its position in shares of Illumina by 14.2% during the third quarter. Voya Investment Management LLC now owns 464,957 shares of the life sciences company’s stock worth $141,449,000 after acquiring an additional 57,798 shares during the last quarter. Voya Financial Advisors Inc. bought a new position in shares of Illumina during the third quarter worth about $428,000. Redpoint Investment Management Pty Ltd raised its position in shares of Illumina by 2.6% during the third quarter. Redpoint Investment Management Pty Ltd now owns 10,853 shares of the life sciences company’s stock worth $3,302,000 after acquiring an additional 278 shares during the last quarter. Chevy Chase Trust Holdings Inc. raised its position in shares of Illumina by 2.0% during the third quarter. Chevy Chase Trust Holdings Inc. now owns 487,032 shares of the life sciences company’s stock worth $148,164,000 after acquiring an additional 9,676 shares during the last quarter. Finally, Carnegie Capital Asset Management LLC bought a new position in shares of Illumina during the third quarter worth about $236,000. 92.26% of the stock is currently owned by hedge funds and other institutional investors.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Further Reading: What is a Roth IRA?
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.